The Record header image

Subscribe  |  The Record Archive  |  Contacts  |  bcbsm.com

June 2022

All Providers

Act now to maintain online access to Blue Cross, BCN information

Online provider toolsThe old adage is true: An ounce of prevention really is worth a pound of cure. Thanks to all of you who’ve registered for and participated in training for our new provider portal, Availity Essentials.

If you haven’t yet had the chance to register and train, time is running out. Blue Cross and BCN’s Provider Secured Services and web-DENIS will have their last day of operation June 21. Beginning June 22, these tools will be retired and no longer available.

Don’t miss out on being able to access information online. Register for Availity Essentials and participate in training now. See Notice: Last day for Provider Secured Services and web-DENIS is June 21 in the May issue of The Record.

Need help?

Here’s where you can find it:

Attention: Availity administrators
After registering for Availity, be sure to set up access to e-referral and Health e-Blue tools. To view the steps Availity administrators need to take to set up these tools, click here.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Reminder: Availity administrators must take action now to ensure access to e-referral and Health e-Blue tools within Availity

Online provider toolsTime is running out. June 21, 2022, is the last day to access e-referral and Health e-Blue℠ through Provider Secured Services and web-DENIS.

If they haven’t already done so, Availity® administrators need to take action to set up access to e-referral and (if appropriate) Health e-Blue. This will ensure users can access these tools through Availity Essentials.

Here’s how these tools are used:

  • The e-referral tool is used to submit requests for referrals and authorizations.
  • The Health e-Blue tools provide patient health reporting on conditions, treatment opportunities, pharmacy claims, diagnosis gaps and more.

Each organization (office, practice or facility) must have at least one Availity administrator. Administrators handle access for other Availity users; users can’t set up their own access. The provider alerts we’ve linked to below describe how to identify the Availity administrator for your organization.

Be sure your Availity administrator sets up access to these tools for all users who need to obtain information for patients who have coverage through Blue Cross Blue Shield of Michigan and Blue Care Network.

If your Availity administrator doesn’t take action, users of these tools won’t be able to access them through Availity and may receive error messages when they try.

Setup instructions

To view step-by-step setup instructions for Availity administrators, see the following provider alerts:

The following videos also show the setup steps:

Additional information

See the Welcome to Availity special edition newsletter for additional information about Availity.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Private duty nursing will soon require prior authorization

Starting Oct. 1, 2022, private duty nursing agencies will have the opportunity to participate in Blue Cross Blue Shield of Michigan’s Traditional and TRUST PPO (commercial) network. Participating agencies can receive direct reimbursement for covered services within the scope of their licensure.

This change will affect Blue Cross benefit plans that cover services these providers are licensed to provide. To find out if a member has coverage, check our provider portal for member benefits and eligibility, or call Provider Inquiry at 1‑800‑344‑8525.

Requirements

Private duty nursing services will require prior authorization effective for dates of service beginning Oct. 1, 2022. We’ll begin accepting requests for prior authorization starting Sept. 1, 2022. Prior authorizations will be submitted through e-referral.

Stay tuned

More information about this program, including enrollment, claims submission requirements and available training, will be coming soon.


2022 COVID-19 HCPCS update: New code added

The Centers for Medicare & Medicaid Services has added a new code as part of its quarterly Health Care Procedure Coding System updates. The code, effective date and Blue Cross Blue Shield of Michigan’s coverage decision are below.

Code Change Coverage comments Effective date
K1034 Added Not covered April 4, 2022

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.


2nd-quarter 2022 early release CPT code update

Category III codes

Code Change Coverage comments Effective date
0714T Deleted Not covered July 1, 2022
0715T Deleted Not covered July 1, 2022
0716T Added Not covered July 1, 2022
0717T Added Not covered July 1, 2022
0718T Added Not covered July 1, 2022
0719T Added Not covered July 1, 2022
0720T Added Not covered July 1, 2022
0721T Added Not covered July 1, 2022
0722T Added Not covered July 1, 2022
0723T Added Not covered July 1, 2022
0724T Added Not covered July 1, 2022
0725T Added Not covered July 1, 2022
0726T Added Not covered July 1, 2022
0727T Added Not covered July 1, 2022
0728T Added Not covered July 1, 2022
0729T Added Not covered July 1, 2022
0730T Added Not covered July 1, 2022
0731T Added Not covered July 1, 2022
0732T Added Not covered July 1, 2022
0733T Added Not covered July 1, 2022
0734T Added Not covered July 1, 2022
0735T Added Not covered July 1, 2022
0736T Added Not covered July 1, 2022
0737T Added Not covered July 1, 2022

Category III codes

Code Change Coverage comments Effective date
90584 Deleted Not covered July 1, 2022

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.


News and information roundup

Following are brief summaries of a few articles that were featured in the May-June issue of Hospital and Physician Update that we thought you might be interested in.

Blue Cross launches new CQI to improve suicide prevention efforts
Blue Cross Blue Shield of Michigan is joining forces with Henry Ford Health to launch a new Collaborative Quality Initiative called the Michigan Mental health Innovation Network for clinical Design, or MiMIND. The goal of MiMIND is to engage psychiatrists, psychologists and primary care physicians in a collaborative approach to improve suicide prevention efforts across Michigan. For more information, click here.

New Pediatric Weight Management Initiative designed to decrease childhood obesity in Michigan
Dr. Martha Walsh, medical director, Clinical Partnerships and Engagement, discusses the problem of childhood obesity and a new pediatric weight management incentive for pediatricians who participate in our Provider-Delivered Care Management program. For more information, click here.

Michigan Opioid Collaborative: Making a difference in patients' lives
The Michigan Opioid Collaborative is transforming the delivery of services to Michiganders with opioid use disorder. To learn more, click here.

Blue Cross focuses on maternal health, announces core measures
As part of a series on health and health care disparities in Michigan, we’re showcasing Blue Cross Blue Shield of Michigan’s efforts to reduce maternal health disparities. For more information, click here.

To subscribe to Hospital and Physician Update or other provider-focused publications, click here.


Billing chart: Blue Cross highlights medical, benefit policy changes

You’ll find the latest information about procedure codes and Blue Cross Blue Shield of Michigan billing guidelines in the following chart.

This billing chart is organized numerically by procedure code. Newly approved procedures will appear under the New Payable Procedures heading. Procedures for which we have changed a billing guideline or added a new payable group will appear under Updates to Payable Procedures. Procedures for which we are clarifying our guidelines will appear under Policy Clarifications. New procedures that are not covered will appear under Experimental Procedures.

You will also see that descriptions for the codes are no longer included. This is a result of recent negotiations with the AMA on use of the codes.

We will publish information about new BCBS groups or changes to group benefits under the Group Benefit Changes heading.

For more detailed descriptions of the BCBSM policies for these procedures, please check under the Medical/Payment Policy tab in Explainer on web-DENIS. To access this online information:

  • Log in to web-DENIS.
  • Click on BCBSM Provider Publications & Resources.
  • Click on Benefit Policy for a Code.
  • Click on Topic.
  • Under Topic Criteria, click on the drop-down arrow next to Choose Identifier Type and then click on HCPCS Code.
  • Enter the procedure code.
  • Click on Finish.
  • Click on Search.
Code* BCBSM changes to:
Basic Benefit and Medical Policy, Group
Variations Payment Policy, Guidelines
NEW PAYABLE PROCEDURES

90671

Basic benefit and medical policy

Pneumococcal conjugate 15-valent vaccine

The pneumococcal conjugate 15-valent vaccine (Vaxneuvance™) is established. It’s been approved by the U.S. Food and Drug Administration, effective July 16, 2021.

On Jan. 28, 2022, Morbidity and Mortality Weekly Report published “Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022”:

“Adults aged 19-64 years with certain underlying medical conditions or other risk factors who have not previously received pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive 1 dose of PCV15. When PCV15 is used, it should be followed by a dose of 23-valent pneumococcal polysaccharide vaccine.

“Adults aged ≥65 years who have not previously received pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive 1 dose of PCV15. When PCV15 is used, it should be followed by a dose of 23-valent pneumococcal polysaccharide vaccine.”

90677

Basic benefit and medical policy

Pneumococcal conjugate 20-valent vaccine

The pneumococcal conjugate 20-valent vaccine (Prevnar 20™) is established. It’s been approved by the U.S. FDA.     

The FDA approved this vaccine (also known as Prevnar 20) on June 8, 2021, for adults 18 years of age and older.

The CPT code for this vaccine is effective July 1, 2021.

On Jan. 28, 2022, Morbidity and Mortality Weekly Report published “Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices – United States, 2022”:

“Adults aged 19-64 years with certain underlying medical conditions or other risk factors who have not previously received pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive 1 dose of PCV20.

“Adults aged ≥65 years who have not previously received pneumococcal conjugate vaccine whose previous vaccination history is unknown should receive 1 dose of PCV20.”

G0452, G9143, S3620, S2800, S3840-S3842, S3844-SS3846, S3849, S3850, S3852-S3854, S3861, S3866, S3870, 81161-81167, 81170, 81187, 81200-81203, 81205-81210, 81212, 81215-81217, 81219-81229, 81234-81237, 81239-81246, 81250-81257, 81260-81268, 81270, 81272, 81273, 81275, 81276, 81287, 81288, 81290-81304, 81310, 81311, 81313-81319, 81321-81327, 81330-81333, 81340-81342, 81350, 81355, 81370-81383, 81400-81408, 81413, 81414, 81422, 81432-81434, 81437-81439, 81442, 81443, 81479, 81490, 81493, 81500, 81503, 81504, 81506-81512, 81518, 81519, 81525, 81535, 81536, 81538-81540, 81545, 81595, 81599, 83950, 83951, 87152, 87153, 88245, 88248, 88249, 88261-88264, 88267, 88269, 88271-88275, 88280, 88283, 88285, 88289, 88291, 88299, 0002M-0004M, 0006M-0010M, 0001U, 0003U-0005U, 0246U, S0265

Basic benefit and medical policy

Genetic testing

The safety and effectiveness of genetic testing and counseling services have been established. They may be considered useful diagnostic options only if the testing results are expected to establish or verify a diagnosis, initiate a treatment plan or alter the patient’s health care management.

Exclusionary criteria have been updated, effective May 1, 2022.

Inclusions:

Genetic testing classified in one of the categories below is established when all criteria are met for each category:

  1. Testing of an affected (symptomatic) individual’s germline DNA to benefit the individual (excluding reproductive testing)
    1. Diagnostic
    2. Prognostic
    3. Therapeutic
  1. Testing cancer cells of an affected individual to benefit the individual
    1. Diagnostic
    2. Prognostic
    3. Therapeutic
  1. Testing an asymptomatic individual to determine future risk of disease

Genetic testing that doesn’t meet the criteria for a specific category is considered experimental.

For the following category of testing, the benefit of testing is for a family member rather than the individual being tested. In this category, the criteria developed are for clinical utility.

  • Testing of an affected individual’s germline to benefit family member or members

Genetic testing is considered experimental when:

  • Testing isn’t considered standard of care, such as when the clinical diagnosis can be made without the use of a genetic test.
  • Testing isn’t clinically appropriate for the patient’s condition (e.g., when it would not change diagnosis or management). Other situations where testing isn’t clinically appropriate include, but are not limited to:
    • Testing performed entirely for nonmedical (e.g., social) reasons
    • Testing not expected to provide a definitive diagnosis that would obviate the need for further testing
  • Testing is performed primarily for the convenience of the patient, physician or other health care provider.
  • Testing would result in outcomes that are equivalent to outcomes using an alternative strategy, and the genetic test is more costly.

Exclusions:

  • Next-generation sequencing panels for conditions other than those listed under the Genetic Testing-NGS Testing of Multiple Genes (Panel) to Identify Targeted Cancer Therapy policy
  • Whole genome or whole exome sequencing for conditions other than those listed under the Genetic Testing-Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders policy
  • Forensic testing for legal purposes
POLICY CLARIFICATIONS

0232T, G0460, G0465, P9020, S9055

Basic benefit and medical policy

Autologous platelet-derived growth factors for wound healing

The use of platelet-rich plasma (i.e., autologous blood-derived growth factor or autologous platelet gel [e.g., Aurix™ / Autologel™ and SafeBlood®]) for the treatment of acute or chronic wounds, including surgical wounds and nonhealing ulcers, hasn’t been established. There is insufficient evidence to draw definitive conclusions regarding the clinical efficacy of autologous platelet concentrate or gel; therefore, they’re considered experimental.

20983, 32994, 50250, 50542, 50593

Experimental
19105, 32999,** 48999,** 0581T

**Unlisted procedure code

Basic benefit and medical policy

Cryosurgical ablation of tumors

The safety and effectiveness of cryosurgical ablation to treat localized renal cell carcinoma have been established. It may be considered a useful therapeutic option when indicated.

The safety and effectiveness of cryosurgical ablation to treat lung cancer have been established. It may be considered a useful therapeutic option when indicated.

The safety and effectiveness of cryosurgical ablation to palliate pain in patients with osteolytic bone metastases have been established. It may be considered a useful therapeutic option when indicated.

The safety and effectiveness of cryosurgical ablation to treat osteoid osteoma have been established. It may be considered a useful therapeutic option when indicated.

Cryosurgical ablation as a treatment of benign or malignant tumors of the breast or pancreas is experimental. It hasn’t been scientifically demonstrated to improve patient clinical outcomes.

Inclusionary criteria have been updated, effective May 1, 2022.

Inclusions:

Renal cell carcinoma with no evidence of metastasis and when either of the following criteria is met:

  • The tumor is no more than 4 cm in its greatest dimension, preservation of kidney function is necessary (i.e., the patient has one kidney or renal insufficiency defined by a glomerular filtration rate, or GFR, of less than 60 mL/min per m2) and standard surgical approach (i.e., resection of renal tissue) is likely to substantially worsen kidney function.
  • The tumor is no more than 4 cm in its greatest dimension and the patient isn’t considered a surgical candidate.

Cryosurgical ablation to treat lung cancer when either of the following criteria is met:

  • The patient has early-stage non-small cell lung cancer and is a poor surgical candidate.
  • The patient requires palliation for a central airway obstructing lesion.

Cryosurgical ablation to palliate pain in patients with osteolytic bone metastases when all the following criteria are met:

  1. Patient is 18 years or older.
  2. One or two painful bone metastasis lesions, 1-11 cm in size.
  3. Patient has failed or is a poor candidate for standard treatments such as radiation or opioids
  4. Patient has pain score ≥ 4 on scale 0-10.
  5. Life expectancy is more than 2 months.
  6. The lesion is > 1 cm away from the spinal cord, brain, other critical nerve structure, large abdominal vessel such as the aorta or inferior vena cava, bowel or bladder.
  7. The coagulation profile is normal (platelets > 50,000 and INR < 1.5).
  8. The site of the lesion isn’t at imminent risk of fracture.
  9. Patient must not have a primary musculoskeletal malignancy, lymphoma or leukemia.

Cryosurgical ablation to treat osteoid osteoma when any of the following criteria are met:

  1. Those who have failed medical therapy.
  2. Those being considered for surgical resection.
  3. Those who have failed previous surgical therapy and have recurrent symptoms or pain.

Exclusions:

Other indications not noted in the policy inclusions

29868, G0428

Basic benefit and medical policy

Meniscal allografts and implants

The safety and effectiveness of meniscal allograft transplants have been established for patients who meet specific criteria. It may be considered a useful therapeutic option when indicated.

Meniscal allograft transplantation has been shown to be safe and effective when performed in combination, either concurrently or sequentially, with autologous chondrocyte implantation, osteochondral allografting or osteochondral autografting for focal articular cartilage lesions. It may be considered a useful therapeutic option when indicated.

Other meniscal implants incorporating materials such as collagen and polyurethane haven’t been shown to be an effective treatment for repairing meniscal defects and are considered experimental.

Inclusionary criteria have been updated, effective May 1, 2022.     

Inclusions:

Meniscal allograft transplantation is established in patients who have had a prior meniscectomy and have symptoms related to the affected side when all the following criteria are met:

  • Adult patients should be too young to be considered an appropriate candidate for total knee arthroplasty or other reconstructive knee surgery (e.g., younger than 55 years)
  • Disabling knee pain with activity that is refractory to conservative treatment
  • Absence or near absence (more than 50%) of the meniscus, established by imaging or prior surgery
  • Documented minimal to absent degenerative changes in the surrounding articular cartilage
  • Surgeon attests that the knee joint is in normal alignment or near normal alignment, or that treatment will include restoration of alignment to normal
  • Surgeon attests that the knee joint has normal or near normal ligamentous stability, or that treatment will result in restoration of ligamentous stability to normal

Meniscal allograft transplantation has been shown to be safe and effective when performed in combination, either concurrently or sequentially, with treatment of focal articular cartilage lesions using any of the following procedures:

  • Autologous chondrocyte implantation
  • Osteochondral allografting
  • Osteochondral autografting

Exclusions:

  • Use of other meniscal implants incorporating materials such as collagen and polyurethane
  • Limited knee range of motion (more than 10 degrees loss of extension; flexion less than or equal to 110 degrees)
  • Loss of strength (must have at least 50% extension strength relative to body weight or other side)
  • Osteoarthritis on radiographs (joint space narrowing, osteophytes)

59076, 59897, S2400, S2401, S2402, S2403, S2404, S2405, S2409

Basic benefit and medical policy

Fetal (prenatal) surgery

Prenatal (fetal) surgery is established for specific congenital abnormalities or conditions. The safety and effectiveness of these surgeries have been proven.

Inclusionary criteria have been updated, effective May 1, 2022. 

Inclusions:

The following prenatal surgical interventions are considered established when there are no maternal contraindications to the surgery and criteria for the surgery are met:

Fetal urinary tract obstruction

Vesicoamniotic shunting is considered established when all the following are present:

  • Megacystis due to urinary tract obstruction
  • Progressive oligohydramnios
  • Adequate renal function
  • No other lethal abnormalities or chromosomal defects

Congenital pulmonary airway malformation

Placement of a thoraco-amniotic shunt or in utero resection of malformed pulmonary tissue is considered established when all the following are present:

  • Congenital pulmonary airway malformation, or CPAM, is identified.
  • The malformations are progressing in size.
  • CPAM volume ratio (CVR) >1.6.
  • Gestational age of one of the following:
    • 32 weeks or less for shunting
    • Less than 27 weeks for in utero resection with plan for continuing pregnancy
    • Greater than 32 weeks for EXIT procedure

Sacrococcygeal teratoma

In utero resection of sacrococcygeal teratoma is considered established when all the following are present:

  • Cardiomegaly with compromised cardiac output,
  • Gestational age of one of the following:
    • 28 weeks or less for resection
    • 32 weeks or less for radiofrequency ablation

Myelomeningocele

Repair of myelomeningocele is considered established when all the following are present:

  • Myelomeningocele is identified, with an upper boundary located between T1 and S1 with evidence of hindbrain herniation
  • Gestational age of 26 weeks or less
  • No other clinically significant fetal abnormalities

Congenital diaphragmatic hernia

Tracheal occlusion in the treatment of congenital diaphragmatic hernia is considered established when all the following are present:

  • Gestational age is less than 30 weeks
  • Evidence of liver herniation
  • Lung-to-head ratio, or LHR, observed-to-expected for gestational age is ≤ 15%

Prenatal surgery should only be performed by facilities with the expertise, multidisciplinary teams, services and facilities to provide the intensive care required for these patients.

Exclusions:

  • Prenatal (fetal) surgery that doesn’t meet criteria listed above.
  • All other applications of prenatal (fetal) surgery including, but not limited to, treatment of congenital heart defects.

Note: Twin-to-twin transfusion syndrome, or TTTS, is addressed in medical policy, “In Utero Laser Therapy for the Treatment of Twin-to-Twin Transfusion Syndrome (TTTS).”

64575, 64585, 64590, 64595, 95972,
L8680, L8681, L8682, L8683, L8685,
L8686, L8687, L8688    

Non-covered:
39599**

**Used to report not otherwise classified procedures

Basic benefit and medical policy

Phrenic nerve stimulation and diaphragm pacing

The safety and effectiveness of phrenic nerve stimulation/diaphragm pacing have been established. It may be a useful therapeutic option when indicated for selected patients, using devices that have been granted full pre-market approval from the FDA.

Coverage criteria has been updated, effective May 1, 2022.  

Inclusions:

Inclusions for FDA-approved device Avery Mark IV™:

Patient is at least 18 years of age, with one of the following:

  • Ventilatory failure from a stable, high spinal cord injury
  • Central alveolar hypoventilation syndrome

And all the following criteria are met:

  • Bilateral clinically acceptable phrenic nerve function (demonstrated with EMG recordings and nerve conduction times)
  • Normal chest anatomy, a normal level of consciousness and the individual has the ability to participate in and complete the training and rehabilitation associated with the use of the device
  • Diaphragm movement with stimulation, visible under fluoroscopy or ultrasound
  • Diaphragmatic/phrenic nerve stimulation allows breathing without the support of a ventilator for at least four continuous hours a day

Exclusions:

  • Individual who is able to breathe spontaneously for four continuous hours or more without use of a ventilator
  • Individual with intact and functional phrenic nerve and diaphragm
  • Individual whose respiratory insufficiency is temporary
  • Motor neuron disease, such as amyotrophic lateral sclerosis, or ALS
  • Treatment of a condition where the phrenic nerve and diaphragm are intact and functional (e.g., chronic obstructive lung disease, central sleep apnea, restrictive lung disease, singultus [hiccups])
  • Underlying cardiac, pulmonary or chest wall disease that prevents spontaneous breathing for more than four continuous hours, even with the use of a phrenic nerve stimulator or diaphragm pacing system

Humanitarian device exemption:

In 2008, NeuRx DPS™ RA/4 received FDA approval through a humanitarian device exemption, or HDE, application for use in patients 18 years of age or older, with stable, high spinal cord injuries. This application is for a medical device intended to benefit patients in the treatment of a disease or condition that affects a relatively small number of individuals in the United States per year. An HDE doesn’t require results of scientifically valid clinical investigations on effectiveness. The FDA only requires sufficient information to determine that the device doesn’t pose unreasonable or significant risk of illness or injury.
On Sept. 29, 2011, NeuRx DPS™ RA/4 (diaphragm pacing system) received an HDE for use in patients 21 years of age and older with amyotrophic lateral sclerosis.

Devices that carry a humanitarian device exemption status aren’t fully approved by the FDA and are considered experimental by Blue Cross Blue Shield of Michigan. However, upon appeal, if the case meets the FDA’s established criteria, individual consideration may be extended.

64999**

**Unlisted procedure code

Basic benefit and medical policy

Peripheral subcutaneous field stimulation and nerve stimulation

The peripheral subcutaneous field stimulation and nerve stimulation medical policy statement has been updated, effective May 1, 2022.

Medical policy statement:

Peripheral nerve stimulation, or PNS, therapy and peripheral subcutaneous field stimulation, or PSFS, are experimental. They haven’t been scientifically demonstrated to improve patient clinical outcomes.

Inclusions and exclusions:

Not applicable

81382, 81479,** 82397, 81554, 82784, 83520, 84999,** 86021, 86140, 86255, 87045, 87046, 87075, 87102, 87177, 87209, 87328, 87329, 87336, 87798, 88346, 88350

**Unlisted procedure code

Basic benefit and medical policy

Genetic and molecular tests

The genetic and molecular tests medical policy statement has been updated, effective May 1, 2022.

Medical policy statement:

Diagnostic, prognostic and therapeutic genetic testing of (1) an affected (symptomatic) individual’s germline to benefit the individual (excluding reproductive testing) or (2) of an asymptomatic individual to determine future risk of disease is considered experimental for the following:

  • Celiac PLUS
  • Crohn’s Prognostic
  • DNA Methylation Pathway Profile
  • GI Effects® (Stool)
  • IBD sgi Diagnostic™
  • ImmunoGenomic® Profile
  • Know Error™
  • ResponseDX®: Colon  
  • Envisia™ Genomic Classifier (Veracyte™)

Inclusions and exclusions:

Not applicable

92227, 92228, 92229,** 92250

**Added as payable effective Jan. 1, 2022.

Basic benefit and medical policy

Retinal care for diabetic retinopathy

The safety and effectiveness of retinal telescreening with digital imaging and manual grading of images as a diagnostic screening technique and for the monitoring and management of diabetic retinopathy have been established.

The clinical utility of FDA-approved digital retinal imaging with image interpretation by artificial intelligence software (e.g., IDX-DR, EyeArt) to screen for diabetic retinopathy has been established.

Retinal telescreening is considered experimental for all other indications.

C9088, J3490, J3590

Basic benefit and medical policy

Zynrelef (Bupivacaine and Meloxicam)

Zynrelef (Bupivacaine and Meloxicam) is payable for the following updated indications, effective Dec. 8, 2021.

Zynrelef contains bupivacaine, an amide local anesthetic, and meloxicam, a nonsteroidal anti-inflammatory drug, or NSAID, and is indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

C9254, J3490, J3590

Basic benefit and medical policy

Vimpat (lacosamide)

Effective Oct. 14, 2021, Vimpat (lacosamide) is payable for the following updated FDA-approved indication:

  • Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 1 month of age and older.

Dosing information:

Pediatric patients 1 month of age to less than 17 years: The recommended dosage is based on body weight and is administered orally twice daily.

G2212

Basic benefit and medical policy

CNP reimbursement for G2212 in OPC location

Effective Jan. 1, 2021, Blue Cross Blue Shield of Michigan will allow reimbursement for procedure code G2212 when the services are rendered by a certified nurse practitioner in an outpatient psychiatric care location.

J0248

Basic benefit and medical policy

Veklury (remdesivir)

Veklury (remdesivir) is payable for the following updated indications, effective Jan. 19, 2022.

Veklury is a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for the treatment of COVID-19 in adults and pediatric patients (12 years and older and weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, who are one of the following:

  • Hospitalized
  • Not hospitalized and have mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death

J3490, J3590

Basic benefit and medical policy

Byooviz (ranibizumab-nuna)

Effective Sept. 17, 2021, Byooviz (ranibizumab-nuna) is covered for the following FDA-approved indications:

Byooviz (ranibizumab-nuna) is a vascular endothelial growth factor, or VEGF, inhibitor that is indicated for the treatment of patients with:

  • Neovascular (wet) age-related macular degeneration, or AMD
  • Macular edema following retinal vein occlusion, or RVO
  • Myopic choroidal neovascularization, or mCNV

Dosage and administration:

For ophthalmic intravitreal injection only.

Neovascular (wet) age-related macular degeneration:

  • Byooviz 0.5 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days).
    • Although not as effective, patients may be treated with three monthly doses followed by less frequent dosing with regular assessment.
    • Although not as effective, patients may also be treated with one dose every three months after four monthly doses. Patients should be assessed regularly.

Macular edema following retinal vein occlusion:

  • Byooviz 0.5 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days).

Myopic choroidal neovascularization:

  • Byooviz 0.5 mg (0.05 mL) is recommended to be initially administered by intravitreal injection once a month (approximately 28 days) for up to three months. Patients may be retreated if needed.

Dosage forms and strengths:

Single-dose glass vial designed to provide 0.05 mL for intravitreal injections: 10 mg/mL solution.

This drug isn’t a benefit for URMBT.

J3490

J3590

Basic benefit and medical policy

Cortrophin (corticotropin)

Effective Nov. 1, 2021, Cortrophin (corticotropin) is covered for the following FDA-approved indications:

Purified Cortrophin Gel is a porcine-derived purified corticotropin (ACTH) in a sterile solution of gelatin. It’s made up of a complex mixture of ACTH, ACTH-related peptides and other porcine pituitary derived peptides.

Purified Cortrophin Gel is indicated in the following disorders:

  • Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
    • Psoriatic arthritis
    • Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
    • Ankylosing spondylitis
    • Acute gouty arthritis
  • Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of:
    • Systemic lupus erythematosus
    • Systemic dermatomyositis(polymyositis)
  • Dermatologic diseases:
    • Severe erythema multiforme (Stevens Johnson syndrome)
    • Severe psoriasis
    • Allergic states:
      • Atopic dermatitis
      • Serum sickness
  • Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:
    • Allergic conjunctivitis
    • Keratitis
    • Iritis and iridocyclitis
    • Diffuse posterior uveitis and choroiditis
    • Optic neuritis
    • Chorioretinitis
    • Anterior segment inflammation
  • Respiratory diseases:
    • Symptomatic sarcoidosis
  • Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythematosus.
  • Nervous system: Acute exacerbations of multiple sclerosis

Dosage and administration:

  • Standard tests for verification of adrenal responsiveness to corticotropin may utilize as much as 80 units as a single injection or one or more injections of a lesser dosage. Verification tests should be performed prior to treatment with corticotropins. The test should utilize the routes of administration proposed for treatment. Following verification dosage should be individualized according to the disease under treatment and the general medical condition of each patient. Frequency and dose of the drug should be determined by considering severity of the disease, plasma and urine corticosteroid levels and the initial response of the patient. Only gradual change in dosage schedules should be attempted after full drug effects have become apparent.
  • In the treatment of acute exacerbations of multiple sclerosis, daily intramuscular doses of 80-120 units for two to three weeks.
  • The chronic administration of more than 40 units daily may be associated with uncontrollable adverse effects.
  • When reduction in dosage is indicated, this should be accomplished gradually by either reducing the amount of each injection or administering injections at longer intervals, or by a combination of both of the above. During reduction of dosage, careful consideration should be given to the disease being treated, the general medical condition of the patient and the duration over which corticotropin was administered.
  • This product may be administered subcutaneously or intramuscularly.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Dosage forms and strengths:

  • Purified Cortrophin Gel is supplied sterile in 5 mL multiple-dose vials containing 80 USP units/mL.

Cortrophin (corticotropin) isn’t a benefit for URMBT.

Various,** 81412, 81443, 81479

**If CPT Tier 1 or Tier 2 molecular pathology codes are available for the specific test, they should be used. If the test hasn’t been codified by CPT, the unlisted molecular pathology code *81479 would be used.

Basic benefit and medical policy

Carrier screening for genetic diseases

Non-targeted carrier screening (panel testing) for autosomal recessive and x-linked genetic disorders have been established. It may be considered a useful diagnostic option when indicated.

The safety and effectiveness of targeted carrier screening for autosomal recessive and x-linked genetic disorders have been established. It may be considered a useful diagnostic option when indicated.

Inclusionary and exclusionary criteria have been updated, effective May 1, 2022. 

Payment policy:

If CPT Tier 1 or Tier 2 molecular pathology codes are available for the specific test, they should be used. If the test hasn’t been codified by CPT, the unlisted molecular pathology code *81479 would be used.

Inclusions:

Non-targeted carrier screening

  • Testing of the female partner for autosomal recessive and x-linked genetic disorders when the female is pregnant or is considering pregnancy. (This is often performed as panel testing.)
  • Testing should include screening for spinal muscular atrophy (SMN1 gene) and cystic fibrosis (CFTR).
  • If the initial testing of the female is positive, then testing in the male partner should be focused on that or those specific gene abnormalities.
  • This testing is only medically necessary once per lifetime. Exceptions may be considered if advances in technology support medical necessity for retesting.

Targeted risk-based carrier screening

This screening is for autosomal recessive and x-linked genetic disorders when the following apply:

  • The couple is pregnant or is considering pregnancy and one of the following is met:
    • One individual is known to be a carrier
    • One or both individuals have a first- or second-degree relative who is affected
      • First-degree includes biological: parent, sibling and child
      • Second-degree includes biological grandparent, aunt, uncle, niece, nephew, grandchildren and half-sibling
    • One or both individuals are members of a population known to have a carrier rate that exceeds a threshold considered appropriate for testing for a particular condition.

And all the following criteria are met (applies to targeted screening):

  • The natural history of the disease is well understood and there is a reasonable likelihood that the disease is one with high morbidity in the homozygous or compound heterozygous state.
  • Alternative biochemical or other clinical tests to definitively diagnose carrier status aren’t available or, if available, provide an indeterminate result or are individually less efficacious than genetic testing.
  • The genetic test has adequate sensitivity and specificity to guide clinical decision-making and residual risk is understood
  • An association of the marker with the disorder has been established

Exclusions:

  • All targeted and non-targeted carrier screening panels not meeting the above criteria
  • Carrier screening of the male partner when the female partner was found not to have risk (i.e., sequential testing)
  • Carrier screening of the male partner at the same time that the female partner is undergoing carrier screening (i.e., simultaneous testing)
  • If previous non-targeted carrier screening or individual targeted gene testing for the genes of interest have been performed, then repeat screening isn’t approved

Various

Service descriptions are to the right

Basic benefit and medical policy

Cosmetic surgery

Reconstructive surgery is an established service when it involves the restoration of a patient to a normal functional status, or when it’s done to repair a defect arising from congenital defects, developmental abnormalities, trauma, infection, involutional defects, tumors or disease. It may be a therapeutic option when indicated.

Cosmetic surgery is performed solely to preserve or enhance appearance or self-esteem. It’s considered not medically necessary.

Inclusionary and exclusionary criteria have been updated, effective May 1, 2022.

Abdominoplasty/panniculectomy:

  • Reconstructive if patient meets policy guidelines. See joint policy “Abdominoplasty.”

Blepharoplasty of lower lids:

  • Cosmetic

Blepharoplasty of upper lids:

  • Cosmetic when done to improve appearance only.
  • Reconstructive if criteria are met. Refer to policy “Blepharoplasty and Repair of Brow Ptosis.”

Breast:

  • Cosmetic if done solely to improve appearance
  • Reconstructive if done following prophylactic mastectomy in high-risk patients. May also be considered reconstructive following medically necessary mastectomy. This would include reconstruction of the nipple and areolar complex. Reconstruction/revision of the contralateral breast may be necessary to provide symmetry between the breasts.

    Note: See medical policy titled “Reconstructive Breast Surgery/Management of Breast Implants” for tattooing the breast/nipple in conjunction with breast reconstruction.

Breast reduction:

  • Cosmetic if done to improve appearance in the absence of functional deficits
  • Reconstructive if policy guidelines are met. See joint policy titled “Reduction Mammoplasty for Breast-Related Symptoms.”

Chemical peels:

  • Cosmetic when done for aging skin (for example, skin damage due to overexposure to sun, etc.), wrinkles, acne scarring or when using chemical peel and hydrating agents that don’t require physician supervision for application
  • Reconstructive when guidelines are met:
    • Chemical peels performed no more than three to four times in a 12-month period are appropriate as follows:
      • Dermal (medium and deep) chemical peels, up to four times per in a 12-month period, used to treat patients with numerous (>10) actinic keratoses or other premalignant skin lesions
      • Epidermal (superficial) peels, up to six times in a 12-month period, used to treat active acne in patients who have failed other therapy

    Note: Requests for chemical peels should be carefully evaluated to determine if the request is primarily cosmetic in nature. Refer to the joint policy titled “Chemical Peels.”

Cheek (malar) or chin (genioplasty) implants:

  • Cosmetic

Correction of telangiectasias or spider veins:

  • Cosmetic

Cryotherapy for skin conditions:

  • Cosmetic when used to treat acne scarring or other dermatologic conditions in which the primary purpose is to change or improve appearance when there is no specific functional deficit or imminent health risk. Cryotherapy isn’t recommended for the treatment of active acne vulgaris.
  • Reconstructive when used to treat actinic keratosis or other pre-cancerous skin lesions

Dermabrasion/microdermabrasion:

  • Cosmetic when used for treatment of wrinkling, hyperpigmentation, or acne scarring. Dermabrasion and microdermabrasion aren’t recommended for the treatment of active acne vulgaris.
  • Reconstructive when used to treat actinic keratosis or other pre-cancerous skin lesions

Dermal fillers:

  • Cosmetic-only used to improve appearance.

Diastasis recti repair absent a true midline hernia:

  • Cosmetic

Electrolysis:

  • Cosmetic
  • Reconstructive if patient meets policy guidelines. Refer to the Transgender Services policy for criteria.

Excision of excessive skin of the thigh, leg, hip, buttock, arm, forearm, hand, submental fat pad or other areas:

  • Cosmetic if the primary purpose is to change or improve appearance when there is no specific functional deficit (e.g., interference with ADLs) or imminent health risk (e.g., infection) that can be removed or improved by the procedure
  • Reconstructive if done to correct a functional problem including, but not limited to, severe rashes or intertrigo, skin ulceration or pain, etc. that hasn’t responded to conventional medical therapy (e.g., topical antifungals, topical or systemic corticosteroids, or local or systemic antibiotics)

Excision of glabellar frown lines:

  • Cosmetic

Fat grafts:

  • Cosmetic

Hairplasty for any form of alopecia:

  • Cosmetic. Coverage may be available only for the treatment of the underlying condition only.

Insertion or injection of prosthetic material to replace absent adipose tissue:

  • Reconstructive only when used to repair a significant deformity from accidental injury, surgery or trauma

Laser resurfacing of the skin:

  • Cosmetic when done to treat wrinkling or aging skin, acne scars, telangiectasias or other skin conditions in which the primary purpose is to change or improve appearance when there is no specific functional deficit or imminent health risk. Laser resurfacing isn’t recommended for the treatment of active acne vulgaris.
  • Reconstructive when done to treat patients with numerous (>10) actinic keratoses or other premalignant or nonmalignant skin lesions when treatment of the individual lesions would be impractical

Laser resurfacing of burn scars (ablative/non-ablative fractional and micro-fractional CO2 laser resurfacing):

  • Reconstructive when used to help correct the abnormal texture and pliability of burn scars

Laser treatment of port wine stains:

  • Reconstructive if done due to functional impairment related to the port wine stain (e.g., bleeding).

Liposuction/suction-assisted lipectomy

  • Cosmetic if it’s the sole procedure done
    • It’s commonly performed on the abdomen (tummy), buttocks (behind), hips, thighs and knees, chin, upper arms, back and calves.
    • Long-term effectiveness of treatment of lower extremity lymphedema has not been established.
  • Reconstructive if done in conjunction with covered reconstruction surgery. For example, if a covered breast reduction is done by conventional means, there may be a need for minor liposuction to smooth the edges of the incisions.

Otoplasty:

  • Cosmetic when done to treat psychological symptomatology or psychosocial complaints related to one’s appearance
  • Reconstructive in following circumstances: when done to correct absent or deformed ears due to congenital deformity/absence, trauma or accidental injury.

Pectus excavatum – minimally invasive repair (e.g., Nuss procedure):

  • Cosmetic: Criteria below aren’t met
  • Reconstructive: Two or more of the following are met:
    • Medical history reveals the patient is symptomatic. Symptoms include shortness of breath with exercise, lack of endurance and chest pain.
    • Physical exam reveals moderatea to severea pectus excavatum deformity that may be symmetric or asymmetric.
    • CT or MRI of the chest indicates severea pectus deformity defined by a Haller index greater than 3.2 or correction index greater than 10%, cardiac or pulmonary compression or displacement.
    • Pulmonary function studies demonstrate a restrictive or obstructive pattern.
    • Cardiology evaluation reveals cardiac compression or displacement, rhythm disturbance, and/or mitral valve prolapse.
    • Psycho-social maladjustment.b

aHaller index score – Normal is 2 or less. Mild deformity is between 2 and 3.2. Moderate deformity is between 3.2 and 3.5. Severe deformity is greater than 3.5.

bTwo additional bullets must be applied with this criteria for surgery to be covered.

Poly-L-lactic acid injection (e.g., Sculptra®):

  • Cosmetic for all indications, including HIV lipoatrophy

Reduction of labia majora and minora, or labiaplasty:

  • Cosmetic. In situations where there is discomfort from the condition, these symptoms can be managed with personal hygiene and avoidance of form-fitting clothes.

Rhinoplasty:

  • Cosmetic if done to improve appearance only.
  • Reconstructive if done for repair of nasal deformity due to trauma, accidental injury or chronic condition affecting the nasal structures (e.g., Wegener’s granulomatosis).

Salabrasion (a technique in which salt or a salt solution is used to abrade the skin, e.g., to remove the pigment from a tattoo or permanent makeup):

  • Cosmetic

Scar revision:

  • Cosmetic if scars are asymptomatic
  • Reconstructive for the revision of symptomatic scars

Tattoo removal:

  • Cosmetic if done for the removal of decorative tattoos
  • Reconstructive if done for the removal of hyperpigmentation resulting from trauma, surgery or other procedures

Testicular prostheses:

  • Reconstructive for replacement of congenitally absent testes, or testes lost due to disease, injury or surgery.

Vaginal rejuventation/vulvovaginal atrophy:

  • Cosmetic
    • Includes use of energy-based devices (e.g., laser, radiofrequency thermal treatment)

Varicose veins:

  • Cosmetic
  • Reconstructive if patients met policy guidelines. Refer to Echoscleortherapy for the Treatment of Varicose Veins and/or Endovenous Ablation for the Treatment of Varicose Veins (e.g., ClariVein®, VenaSeal™, Closure System)

Voice-lifting procedures (e.g., Restylane injections):

  • Cosmetic. Implants or injections of fat or collagen are used to bring vocal cords closer together or to plump cords in an attempt to restore elasticity of vocal cords and reinstate a youthful quality to the patient’s voice.
EXPERIMENTAL PROCEDURES

81554

Basic benefit and medical policy

Procedure code *81554

Diagnostic, prognostic and therapeutic genetic testing of (1) an affected (symptomatic) individual’s germline to benefit the individual (excluding reproductive testing) or (2) of an asymptomatic individual to determine future risk of disease is considered experimental for the following:

  • Celiac PLUS
  • ColonSentry®
  • Crohn’s Prognostic
  • DNA Methylation Pathway Profile
  • FirstSight™
  • GI Effects® (Stool)
  • IBD sgi Diagnostic™
  • ImmunoGenomic® Profile
  • Know Error™
  • ResponseDX®: Colon
  • SEPT9 methylated DNA (for example: ColoVantage®, Epi proColon®)
  • Envisia™ Genomic Classifier (Veracyte™)

Payment policy:

As noted in the web-DENIS message published Dec. 7, 2021, procedure code *81554, used to represent the Envisia™ Genomic Classifier (Veracyte™), was incorrectly loaded as payable, but is considered experimental as of March 7, 2022.

81327, 81479,** 0163U **Used to report not otherwise classified service

Basic benefit and medical policy

Serologic genetic and molecular screening for colorectal cancer

The effectiveness and clinical utility of serologic genetic (i.e., SEPT9 methylated DNA testing [ColoVantage®, Epi proColon®]) or molecular screening for colorectal cancers (i.e., gene expression profiling [ColonSentry®, BeScreened™-CRC, FirstSight™]) haven’t been demonstrated. There is insufficient scientific evidence of the analytical and clinical validity, as well as clinical utility of these tests on patient management and outcomes. They are therefore considered experimental, effective May 1, 2022.

GROUP BENEFIT CHANGES

Sheet Metal Workers Local 80 Insurance Trust Fund

Sheet Metal Workers Local 80 Insurance Trust Fund, group number 71725, is adding the following plan.

Group number: 71725
Alpha prefix: PPO
Platform: NASCO

Plan offered:

Prescription drug

None of the information included in this billing chart is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.

Professional

We invite you to join PGIP as a physician organization

We’re pleased to announce that we’ll accept applications for the Physician Group Incentive Program from new physician organizations from July 1 through July 31, 2022.

PGIP offers incentives to participating physician organizations for improving health care delivery.

To request application materials, send an email to valuepartnerships@bcbsm.com.

About PGIP
The Physician Group Incentive Program was developed with input from providers across Michigan to help improve the quality and efficiency of health care in the state. PGIP facilitates change through a wide range of initiatives, including our nationally recognized Patient-Centered Medical Home program.

Through PGIP, we reward physician organizations for improving health care delivery to their attributed patient population. PGIP-participating physicians are subsequently eligible for value-based reimbursement consideration as a result of program efforts.

A PGIP physician organization consists of physicians participating in our PPO or Traditional network, working together to:

  • Transform systems of care to effectively manage patient populations.
  • Build the infrastructure needed to optimize, measure and monitor quality of care.
  • Promote collaborative relationships.
  • Support the most cost-effective delivery of services to improve patient outcomes.

To learn more

  • If you’re interested in participating in PGIP as an individual practitioner, click here to learn more about PGIP physician organizations.

Practitioners can receive reimbursement for lung health education for patients with Blue Cross Complete

What you need to know
Thanks to the efforts of the INHALE collaborative quality initiative, health care providers who incorporate education into treatment for patients with asthma who have Blue Cross Complete can bill for these services.

Despite a strong correlation between asthma education and improved patient outcomes, fewer than 10% of Michigan asthma patients receive regular self-management education during health care visits, according to medical billing records. Additionally, research has shown that children with asthma who receive regular education have improved lung function, reduced school absenteeism and fewer visits to emergency departments.

Increasing patient education is a core mission of Inspiring Health Advances in Lung Care, or INHALE, a recently launched collaborative quality initiative that is supported by Blue Cross Blue Shield of Michigan. INHALE leadership identified the low education rate as an early priority for the CQI and worked collaboratively with the Asthma Initiative of Michigan to advocate for the Michigan Department of Health and Human Services to accept asthma education as a Medicaid-covered service for Michigan providers.

As a result of these efforts, demonstrating and evaluating patient use of respiratory medications and devices became a covered service for Michigan physicians, practitioners, medical clinics, health departments and child and adolescent health centers providing services to patients with Blue Cross Complete, Blue Cross’ Medicaid plan, in January 2022. The anticipated reimbursement rate is $9.91 per visit through CPT code *94664.

“Drug delivery to the lungs is exceptionally difficult, and teaching patients how to use their medications reduces side effects and improves asthma control and quality of life,” said Njira Lugogo, M.D., INHALE’s program director and Michigan Medicine’s asthma program director. “This change in billing coverage enables providers to receive reimbursement for patient education, which is a critical component of asthma care. Ultimately, the goal is for patients with asthma to live full and productive lives unaffected by asthma.”

For more information

  • To learn more about INHALE, see the article in the May-June issue of Hospital and Physician Update.
  • Providers who have questions about INHALE are encouraged to email contact@inhalecqi.org.

Blue Cross follows CMS guidelines for use of JW modifier to indicate drug waste

As a reminder, Blue Cross Blue Shield of Michigan follows the Centers for Medicare & Medicaid Services’ standard billing guidelines for the use of the JW modifier to identify unused drugs or biologicals from single-use vials or single-use packages that are appropriately discarded. (Multiuse vials aren’t subject to payment for discarded amounts of drug.) This applies to professional claims only.

The JW modifier, billed on a separate line, will provide payment for the amount of the discarded drug or biological.

Example: A single-use vial that is labeled to contain 100 units of a drug has 95 units administered to the patient and five units discarded. The 95 unit dose is billed on one line, while the discarded five units will be billed on another line by using the JW modifier. Both line items would be processed for payment. Providers must record the discarded amounts of drugs and biologicals in the patient’s medical record.

Beginning in the fourth quarter of this year, some drug wastage will be reimbursed at a reduced rate for Blue Cross commercial. Refer to future minimum fee schedule for details.

For more information, check out the CMS article “Billing and Coding: JW Modifier Billing Guidelines.”**

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Reminder: Appropriate use of modifier 59 for Medicare Plus Blue claims

As a reminder, follow the guidelines communicated in the September 2021 Record article when appending modifier 59 on Medicare Plus Blue℠ claims. We have begun editing claim lines when modifier 59 is appended on Medicare Plus Blue claims.

This change aligns with the Centers for Medicare & Medicaid National Correct Coding Initiative, or NCCI, program to ensure the correct coding of services. Modifier 59 is used to indicate that a procedure or service was distinct or independent from other services that aren’t normally reported together but are performed on the same day.

We no longer automatically allow payment for certain procedures billed with modifier 59 and related “X” modifiers when billed with a procedure code on the CMS Procedure to Procedure NCCI List. Only select codes allow modifier 59 to automatically bypass the NCCI code-pair edits.

The additional review assures claims have been coded correctly for more complex situations where an overriding modifier has been appended. Health care providers should code claims to the level of specificity for the services rendered and appropriately append diagnosis codes and modifiers following the guidelines published by the American Medical Association and CMS. The reported services should be supported in the patient’s medical record.

Note: The appeal process won’t change. Continue to submit appeals on the Clinical Editing Appeal Form with the necessary documentation. Also, continue to fax one appeal at a time to avoid processing delays.

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.


Landmark Health program expands to Medicare Advantage members in additional Michigan counties

Blue Cross Blue Shield of Michigan and Blue Care Network have been working with Landmark Health, a mobile provider group, to make high-intensity in-home care available to Medicare Advantage members with multiple chronic conditions. Landmark delivers in-home medical services for patients with multiple chronic conditions to help them stay healthy at home and reduce avoidable emergency department visits and hospital admissions.

Currently, the program is available to a select group of Medicare Plus Blue℠ and BCN Advantage℠ members. Beginning July 1, 2022, we’re expanding the program to include additional members in Southeast Michigan counties, as well as members in the Lansing and Flint areas. Future expansions will make the program available to members in additional counties in Michigan’s Lower Peninsula.

By providing these members with more targeted support, we’ll help to improve their experience and coordination of care, resulting in better overall health and reduced costs. Using a physician-led, interdisciplinary team, the program will complement office-based primary care with services such as:

  • Home-based medical care and documentation of medical conditions and health history by a physician, nurse practitioner or physician assistant
  • In-home routine, urgent and post-acute care visits
  • 24/7 clinical phone support
  • Team-based interdisciplinary care from behavioral health, palliative care and pharmacy providers; dietitians, and social workers
  • Care management, behavior management and medication management
  • Assessment of social determinants of health
  • Education of patients and caregivers
  • Care coordination from nurse care managers
  • Partnership, communication and integration with primary care physician workflows

You’ll receive a list of your patients who are eligible for the program before Landmark contacts the patients.
This program furthers our focus on home care that started with such programs as Hospital Care at Home with Michigan Medicine and High-Intensity Care Management.

For more information on the Landmark program, review our Frequently asked questions for providers document. Look for information about further program expansions in future issues of The Record and BCN Provider News.


Reimbursement for compounded Avastin eye injections changing in August for Medicare Advantage members

For claims received on or after Aug. 1, 2022, reimbursement will change to $160 per eye injected with compounded Avastin® (bevacizumab) eye injections for Medicare Plus Blue℠ and BCN Advantage℠ members.

This change for medical drug claims for Medicare Plus Blue and BCN Advantage members aligns with reimbursement in the marketplace. It’s based on clinical trials that demonstrate the product’s safety and effectiveness.

Here’s the information to include on the claim:

  • HCPCS code number
    • For Medicare Plus Blue: J3590
    • For BCN Advantage: J9035
  • National Drug Code
  • NDC units (example: 0.05 ml)
  • Exact dose in milligrams (example: 1.25 mg)
  • Specific ICD codes pertinent to eye disease

Note: Avastin eye injections don’t require authorization.


Inflectra, Avsola will be preferred infliximab products for pediatric commercial members starting in July

Starting July 1, 2022, the following drugs will be the preferred infliximab products for pediatric Blue Cross Blue Shield of Michigan and Blue Care Network group and individual commercial members:

  • Inflectra® (infliximab-dyyb), HCPCS code Q5103
  • Avsola® (infliximab-axxq), HCPCS code Q5121

The nonpreferred infliximab products will be:

  • Remicade® (infliximab), HCPCS code J1745
  • Renflexis® (infliximab-abda), HCPCS code Q5104

These drugs already require prior authorization for both adult and pediatric members.

How this will affect pediatric members

  • Pediatric members who have an active authorization for a preferred infliximab product as of July 1, 2022, won’t be affected by this change.
  • For pediatric members who have an active authorization for a nonpreferred product, their authorization will remain in effect through Aug. 31, 2022. In addition, we have approved authorizations for Inflectra and Avsola from July 1, 2022, through Aug. 31, 2023, so these members can continue their infliximab therapy without interruption. Health care providers don’t need to submit prior authorization requests for dates of service within this time frame.
  • For pediatric members who will be initiating therapy for an infliximab product, submit a prior authorization request.

How to submit prior authorization requests

Submit prior authorization requests through the NovoLogix® online tool. To learn how, visit ereferrals.bcbsm.com and do the following:

  • For Blue Cross commercial members: Click on Blue Cross and then click on Medical Benefit Drugs. In the Blue Cross commercial column, see the How to submit requests electronically using NovoLogix section.
  • For BCN commercial members: Click on BCN and then click on Medical Benefit Drugs. In the BCN commercial column, see the How to submit requests electronically using NovoLogix section.

Definition of pediatric members

Pediatric members fit into one of these categories:

  • 15 years old or younger, regardless of weight
  • 16 through 18 years old who weigh 50 kilograms or less

Some Blue Cross commercial groups not subject to these requirements

For Blue Cross commercial groups, this authorization requirement applies only to groups that currently participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit. To determine whether a group participates in the prior authorization program, see the Specialty Pharmacy Prior Authorization Master Opt-in/out Group List.

List of requirements

For a full list of requirements related to drugs covered under the medical benefit, see the Blue Cross and BCN utilization management medical drug list for Blue Cross commercial and BCN commercial members.
Authorization isn't a guarantee of payment. As always, health care practitioners should verify eligibility and benefits for our members.


Here are time frames for determinations on authorization requests for acute inpatient medical admissions

The time frame within which Blue Cross Blue Shield of Michigan and Blue Care Network must make a determination on a request to authorize an acute inpatient medical admission depends on the type of request.

We’ve updated the document Submitting acute inpatient authorization requests: Frequently asked question for providers to include information on the time frames for determinations. You can access that document on these webpages:

For easy reference, we also included the details in the table below. This information applies only to acute inpatient medical admissions, not to behavioral health inpatient admissions.

Request for…

Time frame for determination

Requirements

Standard set by …

Blue Cross commercial

Medicare Plus Blue℠

BCN commercial

BCN Advantage℠

Preservice expedited organization determination

Within 72 hours of receipt of request

CMS NCQA

Concurrent expedited organization determination

Within 72 hours of receipt of request

NCQA

Preservice standard organization determination

Within 14 calendar days of receipt of request

CMS NCQA

Concurrent standard organization determination

Within 14 calendar days of receipt of request

 

CMS

Postservice standard organization determination

Within 30 calendar days of receipt of request

CMS NCQA

Here’s more information about the types of requests:

  • Standard: Request to reimburse for services.
  • Expedited: Request when standard time frame could seriously jeopardize the life or health of a member or the member’s ability to regain maximum function. Requires that a physician attest to the need for an expedited request.
  • Preservice: Request is received prior to receipt of care.
  • Concurrent: Request is received while member is receiving care.
  • Postservice: Request is received after member has been discharged.

Reminders:

  • We don’t use the Centers for Medicare & Medicaid Services two-midnight rule; we require authorization for all hospital admissions, both Medicare Advantage and commercial.
  • Our authorization program is oriented toward providers, not members. We don’t deny care, services or treatment. Our program determines the appropriate level of care for reimbursement (observation versus inpatient).

CareCentrix removes HIPPS questionnaire from HomeBridge portal

On March 20, 2022, CareCentrix® removed the HIPPS Questionnaire from the HomeBridge® portal. CareCentrix now accepts Health Insurance Prospective Payment System, or HIPPS, codes generated by home health agencies.

Blue Cross Blue Shield of Michigan and CareCentrix made this change, which affects Medicare Plus Blue℠ members who receive services in Michigan, based on feedback from home health agencies.

This change doesn’t affect Medicare Plus Blue members who receive services outside of Michigan or BCN Advantage℠ members.

For more information about working in the HomeBridge portal, see the CareCentrix document titled Accessing and Navigating the Updated HIPPS Template in the CareCentrix Provider Portal.**

For more information about this change and reminders, see this news item on ereferrals.bcbsm.com.

CareCentrix is an independent company that manages the authorization of home health care services for Blue Cross Blue Shield of Michigan and Blue Care Network members who have Medicare Advantage plans.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Blue Cross payment policy for hyperbaric oxygen therapy will align with our medical policy

In support of correct coding and payment accuracy, Blue Cross Blue Shield of Michigan’s payment policy for hyperbaric oxygen therapy will align with our medical policy.
 
Claims submitted with CPT code *99183 and HCPCS code G0277 will be evaluated to ensure that they include a diagnosis code that aligns with our established medical policy.

  • *99183 — Hyperbaric oxygen therapy
  • G0277 — Hyperbaric oxygen under pressure, per 30-minute interval

Claims that don’t contain a requisite diagnosis may receive a denial.   

The medical policy for hyperbaric oxygen therapy is available online.


Prior authorization requirements change for radiology code *71271

Radiology code *71271 no longer requires prior authorization through AIM Specialty Health® for these members:

  • Medicare Plus Blue℠
  • Blue Care Network commercial
  • BCN Advantage℠

This information is intended to clarify earlier communications about prior authorization requirements for this procedure code.

We’ve updated the document Procedures that require prior authorization by AIM Specialty Health: Cardiology, radiology (high technology) and sleep studies (in lab) to reflect this.

As a reminder, AIM Specialty Health makes authorization determinations for select high-tech imaging services and other services performed in freestanding facilities, outpatient hospital settings, ambulatory surgery centers and physician offices.

For additional information about submitting prior authorization requests to AIM, visit these webpages at ereferrals.bcbsm.com:

AIM Specialty Health is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage authorizations for select services.


Lunch and learn webinars focus on risk adjustment, coding

Action item

Register now for webinars that can improve your coding processes.

Physicians and coders are invited to attend webinars that provide new information on documentation and coding of common and challenging diagnoses. These live lunchtime educational sessions will include an opportunity to ask questions.

Current schedule
All sessions start at noon Eastern time and generally run for 30 minutes. Click on a link below to sign up.


Session Date

Topic

Registration

June 16

Coding for Heart Disease and Heart Arrythmias

Register here

July 19

Coding for Vascular Disease

Register here

Aug. 17

Coding History and Rheumatoid Arthritis

Register here

Sept. 22

Coding Heart Failure, COPD, CHF

Register here

Oct. 11

2023 Updates for ICD-10 CM

Register here

Nov. 16

Coding Scenarios for Specialty Providers and PCPs

Register here

Dec. 8

E/M Coding Review and Scenarios

Register here

If you have any questions about the sessions, contact April Boyce at aboyce@bcbsm.com. If you have questions regarding registration, email Patricia Scarlett at pscarlett@bcbsm.com.


Important updates to training courses; new on-demand training available

Action item
Visit our provider training site to find important updates to existing training and new resources on topics that are important to your role.

In support of Blue Cross Blue Shield of Michigan and Blue Care Network’s transition to a new provider portal, Availity®, Provider Experience has updated many of its existing training courses with new screen examples and steps to align with the change. To access these courses, follow the steps at the end of this article.

Availity
For training related to our new provider portal, go to the Availity Get Up to Speed with Training webpage designed specifically for Blue Cross and BCN. This page provides you with the latest dates and times for Blue Cross- and BCN-specific webinars. You can register for the webinars, download handouts and view webinar recordings from this website by clicking on the link and signing into Availity.

For more information about Availity, see the following articles in this issue of The Record:

Training resources from Provider Experience
Provider Experience also continues to offer training resources for health care providers and staff. On-demand courses are designed to help you work more efficiently with Blue Cross and BCN.
We recently added the following new learning opportunity:

  • Risk adjustment review recorded webinar — This lunch and learn webinar shares new information on documentation and coding of common and challenging diagnoses. Topics include a review of risk adjustment and hierarchical condition categories.

Our provider training site is available to enhance the training experience for health care providers and staff. To request access, complete the following steps:

  • Open the registration page.
  • Complete the registration. We recommend using the same email you use to communicate with Blue Cross for provider-related needs. This will become your login ID.
  • Follow the link to log in.

If you need assistance creating your login ID or navigating the site, contact ProviderTraining@bcbsm.com.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.


Register now for 2022 virtual provider symposium sessions

This year’s virtual provider symposiums will continue in June. Physicians, physician assistants, nurse practitioners, nurses and coders can receive continuing education credits for attending. You’re welcome to register for any session listed below.

We are Stars — HEDIS® and Star measure details and exclusions: For physicians and office staff responsible for closing gaps in care related to quality adult measures.

Click below to register:

Patient Experience — Providing great service 2.0: For physicians and office staff responsible for creating positive patient experiences.

Select a date to register:

Medical record documentation and coding update: For physicians, coders, billers and administrative staff.

Select a date to register:

Questions?
Contact Ellen Kraft at ekraft@bcbsm.com if you have questions about the sessions or Patricia Scarlett at pscarlett@bcbsm.com if you have registration questions.

HEDIS®, which stands for Healthcare Effectiveness Data and Information Set, is a registered trademark of the National Committee for Quality Assurance, or NCQA.

Accreditation statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Minnesota Medical Association and Blue Cross Blue Shield of Michigan. The Minnesota Medical Association (MMA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Statement: The Minnesota Medical Association designates this internet live activity for a maximum of 4.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Survey offers insights into how we’re meeting expectations of health care providers

What you need to know

  • We surveyed health care providers and office staff to understand how they feel about their experiences with us.
  • Blue Cross outperforms other health plans on all experience measures.
  • Providers are satisfied with our efforts to improve health care in Michigan.
  • Providers and office staff identified operational areas where we can do better.

We conducted 10-minute surveys of Blue Cross Blue Shield of Michigan physicians and office staff, beginning late last year. The physician survey was fielded from Nov. 9 through Dec. 22, 2021, while the office staff survey was open from Nov. 12 through Jan. 3, 2022. For more details about the survey methodology, see the “How we conducted the survey” section at end of this article.

Following is an overview of the survey findings.

Blue Cross scores high on commitment to health and providing support for patient care
Blue Cross Blue Shield of Michigan and Blue Care Network received high marks from providers and office staff on many elements of their experiences with us, including the value of provider network participation, our commitment to improving health care in Michigan and the support we offer to help deliver patient care. In fact, Blue Cross outperforms other health plans on all experience measures.

However, they want us to do more to enhance their understanding of which procedures need authorization. Also, physicians indicated they want to have input into new programs and policies that affect patient care.

For providers, the highest ratings were for the overall relationship with Blue Cross, our demonstrated commitment to improve health and health care in Michigan and the value of participating in the provider network. Here are several key metrics:

  • Seventy-six percent of providers said they were somewhat or very satisfied (score of 6 through 10 on a 0 to 10 scale) with the value of participating in the provider network. 
  • Seventy-three percent of providers were very satisfied with our dedicated commitment to improve health and health care in Michigan.
  • Seventy-four percent of providers were very satisfied in their overall relationship with Blue Cross.
  • Seventy-three percent of providers were very satisfied with the ease of doing business with Blue Cross.
  • Seventy-one percent of providers were somewhat or very satisfied with the overall support Blue Cross provides to help deliver patient care.
  • Sixty-five percent of providers were somewhat or very satisfied with the support and resources offered during the pandemic.
  • Seventy-one percent of providers said they were somewhat or very satisfied with the direction Blue Cross is headed for the future.

By comparison, other health plans in Michigan scored in the range of 50% to 60% satisfaction on the above statements.

Physicians want a partnership
Physicians want to have a say in the strategic decisions Blue Cross is considering when it will affect patient care and they also want fair compensation. Gathering feedback from research efforts, such as the following, is one way that we’re listening to providers.

  • Fifty-four percent of providers agreed or strongly agreed that Blue Cross trusts their expertise as a medical doctor.
  • Forty-nine percent of providers somewhat or strongly agree that Blue Cross is a partner to their practice by providing tools and support to provide quality care to their patients.
  • Fifty-five percent of providers somewhat or strongly agree that Blue Cross provides fair compensation.

Provider Inquiry can be improved
Long wait times for provider inquiry help are a primary concern for office staff. Only 25% of office staff respondents agree that Provider Inquiry has gotten somewhat or much better in the last 12 months. However, 80% of office staff were somewhat or very satisfied that Provider Inquiry information is accurate regarding patient eligibility and benefits.

In addition:

  • Sixty-nine percent of office staff said they were somewhat or very satisfied with the ease of finding accurate patient eligibility and benefits information.
  • Sixty-three percent of office staff said they were somewhat or very satisfied with representatives’ ability to resolve issues and concerns.

Prior authorizations
Understanding when prior authorizations are required is an ongoing pain point for physicians and office staff. Fifty percent of Blue Cross providers and office staff somewhat or strongly agree that they know when prior authorization is required.

Nearly half (47%) of physicians and office said they understand Blue Cross prior authorization and medical criteria. And approximately one-third (31%) of office staff respondents said it was easy to determine which medical services require authorization.

Our move to Availity®
Providing extra support and education around the benefits of Availity may ease hesitancy toward the switch from web-DENIS. Among those who have experience with Availity, 6 in 10 are satisfied, while others are hesitant to switch from web-DENIS to Availity.

To help with the transition to Availity, we’ve provided communications in our newsletters for the past year and have recently posted a special edition newsletter about Availity on March 16, including how to register and how to access training.

Providers find our communications helpful
The majority of providers find Blue Cross and BCN communications informative and relevant with heaviest utilization among office staff. Fifty-three percent of providers and 79% of office staff said they somewhat or strongly agree that our provider communications keep them abreast of information relevant to them. The Record and BCN Provider News were the most popular and useful publications for office staff. Hospital & Physician Update isthe most useful for physicians.

How we conducted the survey
Our survey of physicians and office staff was administered by Gongos, an independent firm that contracts with Blue Cross.

  • Physicians completed the survey online and were sent invitations by email and fax. Additional reminders were sent by fax as well.
  • Invitations for office staff were sent by mail, offering the option to complete online or by mail. Postcard reminders were also sent.
  • A total of 428 physicians and 283 office staff completed a survey.

Keep your Provider Authorization form updated

Blue Cross Blue Shield of Michigan is dedicated to safeguarding the protected health information of its members. These safeguards include completion of a Trading Partner Agreement and Provider Authorization form as part of the electronic data interchange setup process. All EDI trading partners must complete the TPA and Provider Authorization form before they can exchange PHI with Blue Cross.

The terms of the TPA require you to notify Blue Cross of any changes in your trading partner information, so it’s important to keep your Provider Authorization form up to date. Updating the form also ensures information is routed to the proper destination.

Update the form when you:

  • Change service bureaus or clearinghouses.
  • Change software vendors.
  • Change billing services.
  • Change submitter IDs.
  • Change 835-file recipients.
  • Change unique 835 receivers or trading partner IDs.
  • Decide you no longer want to receive 835 remittance files.

Review the form when you:

  • Join a new group practice.
  • Leave a group practice and start billing using your own NPI.
  • Hire a new billing service.
  • Start submitting claims through a clearinghouse or when you’ve changed clearinghouses.
  • Select a new destination for your 835.

You don’t need to update the Provider Authorization form if your submitter and trading partner IDs don’t change.

How to change your EDI setup
To make changes to your EDI setup, log in to the Trading Partner Agreement webpage. Or follow the steps below to arrive at the TPA login page at bcbsm.com/providers/help/edi:

  • Visit bcbsm.com/providers.
  • Click on Help.
  • Scroll to the Provider online tools section and click on How do I sign up for Electronic Data Interchange?
  • Click on Trading Partner Agreements.
  • Click on Complete or Update a Provider Authorization.

If you have any questions about EDI enrollment, contact the EDI Help Desk at EDISupport@bcbsm.com. Include your billing NPI and submitter ID with all correspondence.


Some resources, fact sheets about cancer screenings to share with patients

This is part of an ongoing series of articles focusing on the tools and resources available to help your patients who are FEP members manage their health.

Cancer is the second leading cause of death in the U.S., according to the Centers for Disease Control and Prevention. Regular screenings for breast, cervical and colorectal cancer offer the best chance to find cancer early when treatment is most effective.  

To help people keep track of the screenings they need, the CDC created fact sheets about cancer prevention and the importance of cancer screenings.

Share these fact sheets with your patients:

The CDC offers additional resources on cancer screenings and prevention for health care providers that include continuing medical education courses,** simulations,** webinars,** screening guidelines and other resources.**

The Blue Cross and Blue Shield Federal Employee Program® covers cancer screenings for colorectal, cervical and breast cancer. There are no out-of-pocket costs for members when they have their screenings once per calendar year and the procedure is performed by a Preferred provider.

If you or a member has questions about FEP benefits, call Customer Service at 1-800-482-3600 or go online to fepblue.org.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Acute low back pain doesn’t always require imaging

This is part of an ongoing series of articles focusing on the tools and resources available to help your patients who are FEP members manage their health.

Low back pain is among the most common causes of disability and lost productivity in the U.S. More than 80% of the population will experience low back pain in their lifetime, according to the National Institute of Neurological Disorders and Stroke. Many patients with low back pain receive routine spinal imaging, such as X-rays, CT scans or MRIs. However, imaging isn’t recommended for most patients with acute low back pain in the absence of red flags.

Red flags include:

  • Severe or progressive neurologic deficits (loss of ability to move an arm or leg on one side of your body)
  • Fever
  • Sudden back pain with spinal tenderness
  • Trauma
  • Loss of bladder control or bowel control

In the absence of red flags, the American Association of Neurological Surgeons recommends a conservative approach, such as:

  • Instructing the patient to stay active as tolerated by pain
  • Avoiding bed rest
  • Doing back exercises and stretches
  • Injury prevention
  • Using over-the-counter pain relievers

The Michigan Quality Improvement Consortium guideline for Management of Acute Low Back Pain in Adults** provides recommendations for assessment, diagnosis and treatment of acute low back pain in adults.

Share this information with your patients, and if you or a member has questions about Blue Cross and Blue Shield Federal Employee Program® benefits, call Customer Service at 1-800-482-3600 or go online to fepblue.org.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.

Facility

CQI incentive program now available for ambulatory surgery facilities

Our Collaborative Quality Initiatives are statewide, clinician-led quality improvement initiatives that address many of the most common areas of surgical and medical care in Michigan. Historically, the CQI program has involved the engagement and participation of hospitals and physician practices in CQI activities.

We recently expanded the program to include procedures performed at independent, free-standing ambulatory surgery facilities.** As a result, we’ve developed a CQI incentive program for ambulatory surgery facilities to support their participation and engagement in specific CQIs.  

This CQI incentive will reward ambulatory surgery facilities that meet all of these requirements:

  • They participate in our CQI program.
  • They contribute data to the statewide registry.
  • They learn and share best practices.
  • They participate in continuous quality improvement activities.

Ambulatory surgery facilities that participate in this CQI incentive program will be eligible for a facility fee increase of 1%, or 101% of the standard fee schedule amount for Blue Cross Blue Shield of Michigan and Blue Care Network commercial members. 

This increase will apply to all services reimbursed at the facility level. The following CQIs are participating in the CQI incentive program for ambulatory surgery facilities:

  • The Michigan Arthroplasty Registry Collaborative Quality Initiative (marcqi.org***)
  • The Michigan Spine Surgery Improvement Collaborative (mssic.org***)

Ambulatory surgery facilities must meet specific eligibility requirements, including procedure volumes and participation expectations, to be involved with this program.

To learn more about the eligibility requirements and participation expectations for the ambulatory surgery facilities CQI incentive, refer to the 2022 Blue Cross Blue Shield of Michigan and Blue Care Network Collaborative Quality Initiative ASF CQI Incentive Program for Independent Free-Standing Ambulatory Surgery Facilities.

Background information on our CQI program
With the Collaborative Quality Initiatives model, participants submit clinical condition- or procedure-specific data to a center responsible for analyzing the data to identify best practices and opportunities for improvement.

Quality improvement interventions are implemented, and collaborative participants meet regularly to share and learn best practices based on relevant, timely clinical data. For more information, visit our Collaborative Quality Initiatives site.

**Independent free-standing ASFs are entities that operate exclusively for the purpose of providing outpatient surgical services to patients and aren’t associated with one or more of Blue Cross Blue Shield of Michigan’s participating hospital agreements related to hospital outpatient services.

***Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Medicare Advantage post-acute care: New 7-day limit on documents in naviHealth’s nH Access portal

Effective June 3, 2022, documents for Medicare Plus Blue℠ and BCN Advantage℠ members will be available within nH Access™ for only seven days from the day they were posted.

If you need to access a document after it’s been removed from nH Access, contact your naviHealth care coordinator.

If you have questions about this change, contact your local naviHealth provider relations manager. If you aren’t sure who your naviHealth provider relations manager is, send an email to umproviderconcerns@bcbsm.com.

Note: Since Feb. 11, 2022, documents have been available in the nH Access portal for 30 days.

naviHealth is committed to improving the post-acute care experience for our Medicare Advantage members. As part of this commitment, naviHealth provides access to patient information and documentation during the prior authorization process by making documents available through nH Access.

As a reminder, naviHealth:

  • Authorizes patient-driven payment model levels during the patient's skilled nursing facility stay (from preservice through discharge)
  • Authorizes patient-driven payment model levels based on medical-necessity review and their proprietary naviHealth Predict functional assessment
  • Works with skilled nursing facilities to ensure billers submit proper PDPM levels for reimbursement

For more information, see Post-acute care services: Frequently asked questions for providers.

naviHealth Inc. is an independent company that manages authorizations for post-acute care services for Blue Cross Blue Shield of Michigan and Blue Care Network members who have Medicare Advantage plans.


We’re designating preferred and nonpreferred IV iron therapy replacement drugs for Medicare Advantage members

Starting Aug. 8, 2022, we’re designating certain intravenous iron replacement therapy drugs as preferred or nonpreferred for our Medicare Plus Blue℠ and BCN Advantage℠ members. These drugs are covered under members’ medical benefits.

If you are currently treating one of our Medicare Advantage members with a drug that will be designated as nonpreferred, we encourage you to transition to them to a preferred drug as soon as possible.

Preferred medications won’t require prior authorization
The preferred IV iron therapy replacement medications are:

  • Ferrlecit® (sodium ferric gluconate), HCPCS code J2916        
  • Feraheme® (ferumoxytol), HCPCS code Q0138
  • Venofer® (iron sucrose), HCPCS code J1756
  • INFeD® (iron dextran), HCPCS code J1750

Nonpreferred medications will require prior authorization
The nonpreferred IV iron therapy replacement medications are:

  • Injectafer® (ferric carboxymaltose), HCPCS code J1439
  • Monoferric® (ferric derisomaltose), HCPCS code J1437

For dates of service on or after Aug. 8, 2022, we’ll require prior authorization for these nonpreferred IV iron therapy medications.

Submit prior authorization requests using the NovoLogix® online tool.

Exception: In line with Original Medicare guidelines, Injectafer and Monoferric won’t require prior authorization when members receive them through a dialysis facility. Refer to the ESRD PPS Drug Designation Process** guidelines published by the Centers for Medicare & Medicaid Services.

When prior authorization is required
We require prior authorization for the nonpreferred drugs when they are administered in any site of care other than inpatient hospital (place of service code 21) and are billed as follows:

  • Electronically through an 837P transaction or on a professional CMS-1500 claim form
  • Electronically through an 837I transaction or by using the UB04 claim form for a hospital outpatient type of bill 013x

Submitting prior authorization requests
Submit requests for the nonpreferred drugs using the NovoLogix online tool. It offers real-time status checks and immediate approvals for certain medications.

If you have access to the Availity® Essentials provider portal, you already have access to NovoLogix. If you need to request access to Availity, follow the instructions on the Register for web tools webpage at bcbsm.com/providers.

After you’ve logged in to Availity, click on Payer Spaces and then click on the BCBSM and BCN logo. This will take you to the Blue Cross and BCN payer space, where you’ll find links to the NovoLogix tools on the Applications tab.

List of requirements
For a list of requirements related to drugs covered under the medical benefit, see this list: Medical Drug and Step Therapy Prior Authorization List for Medicare Plus Blue PPO and BCN Advantage members.

We’ll update the list to reflect these changes prior to the effective date.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Reimbursement for compounded Avastin eye injections changing in August for Medicare Advantage members

For claims received on or after Aug. 1, 2022, reimbursement will change to $160 per eye injected with compounded Avastin® (bevacizumab) eye injections for Medicare Plus Blue℠ and BCN Advantage℠ members.

This change for medical drug claims for Medicare Plus Blue and BCN Advantage members aligns with reimbursement in the marketplace. It’s based on clinical trials that demonstrate the product’s safety and effectiveness.

Here’s the information to include on the claim:

  • HCPCS code number
    • For Medicare Plus Blue: J3590
    • For BCN Advantage: J9035
  • National Drug Code
  • NDC units (example: 0.05 ml)
  • Exact dose in milligrams (example: 1.25 mg)
  • Specific ICD codes pertinent to eye disease

Note: Avastin eye injections don’t require authorization.


Inflectra, Avsola will be preferred infliximab products for pediatric commercial members starting in July

Starting July 1, 2022, the following drugs will be the preferred infliximab products for pediatric Blue Cross Blue Shield of Michigan and Blue Care Network group and individual commercial members:

  • Inflectra® (infliximab-dyyb), HCPCS code Q5103
  • Avsola® (infliximab-axxq), HCPCS code Q5121

The nonpreferred infliximab products will be:

  • Remicade® (infliximab), HCPCS code J1745
  • Renflexis® (infliximab-abda), HCPCS code Q5104

These drugs already require prior authorization for both adult and pediatric members.

How this will affect pediatric members

  • Pediatric members who have an active authorization for a preferred infliximab product as of July 1, 2022, won’t be affected by this change.
  • For pediatric members who have an active authorization for a nonpreferred product, their authorization will remain in effect through Aug. 31, 2022. In addition, we have approved authorizations for Inflectra and Avsola from July 1, 2022, through Aug. 31, 2023, so these members can continue their infliximab therapy without interruption. Health care providers don’t need to submit prior authorization requests for dates of service within this time frame.
  • For pediatric members who will be initiating therapy for an infliximab product, submit a prior authorization request.

How to submit prior authorization requests

Submit prior authorization requests through the NovoLogix® online tool. To learn how, visit ereferrals.bcbsm.com and do the following:

  • For Blue Cross commercial members: Click on Blue Cross and then click on Medical Benefit Drugs. In the Blue Cross commercial column, see the How to submit requests electronically using NovoLogix section.
  • For BCN commercial members: Click on BCN and then click on Medical Benefit Drugs. In the BCN commercial column, see the How to submit requests electronically using NovoLogix section.

Definition of pediatric members

Pediatric members fit into one of these categories:

  • 15 years old or younger, regardless of weight
  • 16 through 18 years old who weigh 50 kilograms or less

Some Blue Cross commercial groups not subject to these requirements

For Blue Cross commercial groups, this authorization requirement applies only to groups that currently participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit. To determine whether a group participates in the prior authorization program, see the Specialty Pharmacy Prior Authorization Master Opt-in/out Group List.

List of requirements

For a full list of requirements related to drugs covered under the medical benefit, see the Blue Cross and BCN utilization management medical drug list for Blue Cross commercial and BCN commercial members.
Authorization isn't a guarantee of payment. As always, health care practitioners should verify eligibility and benefits for our members.


Here are time frames for determinations on authorization requests for acute inpatient medical admissions

The time frame within which Blue Cross Blue Shield of Michigan and Blue Care Network must make a determination on a request to authorize an acute inpatient medical admission depends on the type of request.

We’ve updated the document Submitting acute inpatient authorization requests: Frequently asked question for providers to include information on the time frames for determinations. You can access that document on these webpages:

For easy reference, we also included the details in the table below. This information applies only to acute inpatient medical admissions, not to behavioral health inpatient admissions.

Request for…

Time frame for determination

Requirements

Standard set by …

Blue Cross commercial

Medicare Plus Blue℠

BCN commercial

BCN Advantage℠

Preservice expedited organization determination

Within 72 hours of receipt of request

CMS NCQA

Concurrent expedited organization determination

Within 72 hours of receipt of request

NCQA

Preservice standard organization determination

Within 14 calendar days of receipt of request

CMS NCQA

Concurrent standard organization determination

Within 14 calendar days of receipt of request

 

CMS

Postservice standard organization determination

Within 30 calendar days of receipt of request

CMS NCQA

Here’s more information about the types of requests:

  • Standard: Request to reimburse for services.
  • Expedited: Request when standard time frame could seriously jeopardize the life or health of a member or the member’s ability to regain maximum function. Requires that a physician attest to the need for an expedited request.
  • Preservice: Request is received prior to receipt of care.
  • Concurrent: Request is received while member is receiving care.
  • Postservice: Request is received after member has been discharged.

Reminders:

  • We don’t use the Centers for Medicare & Medicaid Services two-midnight rule; we require authorization for all hospital admissions, both Medicare Advantage and commercial.
  • Our authorization program is oriented toward providers, not members. We don’t deny care, services or treatment. Our program determines the appropriate level of care for reimbursement (observation versus inpatient).

CareCentrix removes HIPPS questionnaire from HomeBridge portal

On March 20, 2022, CareCentrix® removed the HIPPS Questionnaire from the HomeBridge® portal. CareCentrix now accepts Health Insurance Prospective Payment System, or HIPPS, codes generated by home health agencies.

Blue Cross Blue Shield of Michigan and CareCentrix made this change, which affects Medicare Plus Blue℠ members who receive services in Michigan, based on feedback from home health agencies.

This change doesn’t affect Medicare Plus Blue members who receive services outside of Michigan or BCN Advantage℠ members.

For more information about working in the HomeBridge portal, see the CareCentrix document titled Accessing and Navigating the Updated HIPPS Template in the CareCentrix Provider Portal.**

For more information about this change and reminders, see this news item on ereferrals.bcbsm.com.

CareCentrix is an independent company that manages the authorization of home health care services for Blue Cross Blue Shield of Michigan and Blue Care Network members who have Medicare Advantage plans.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Blue Cross payment policy for hyperbaric oxygen therapy will align with our medical policy

In support of correct coding and payment accuracy, Blue Cross Blue Shield of Michigan’s payment policy for hyperbaric oxygen therapy will align with our medical policy.
 
Claims submitted with CPT code *99183 and HCPCS code G0277 will be evaluated to ensure that they include a diagnosis code that aligns with our established medical policy.

  • *99183 — Hyperbaric oxygen therapy
  • G0277 — Hyperbaric oxygen under pressure, per 30-minute interval

Claims that don’t contain a requisite diagnosis may receive a denial.   

The medical policy for hyperbaric oxygen therapy is available online.


Prior authorization requirements change for radiology code *71271

Radiology code *71271 no longer requires prior authorization through AIM Specialty Health® for these members:

  • Medicare Plus Blue℠
  • Blue Care Network commercial
  • BCN Advantage℠

This information is intended to clarify earlier communications about prior authorization requirements for this procedure code.

We’ve updated the document Procedures that require prior authorization by AIM Specialty Health: Cardiology, radiology (high technology) and sleep studies (in lab) to reflect this.

As a reminder, AIM Specialty Health makes authorization determinations for select high-tech imaging services and other services performed in freestanding facilities, outpatient hospital settings, ambulatory surgery centers and physician offices.

For additional information about submitting prior authorization requests to AIM, visit these webpages at ereferrals.bcbsm.com:

AIM Specialty Health is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage authorizations for select services.


Lunch and learn webinars focus on risk adjustment, coding

Action item

Register now for webinars that can improve your coding processes.

Physicians and coders are invited to attend webinars that provide new information on documentation and coding of common and challenging diagnoses. These live lunchtime educational sessions will include an opportunity to ask questions.

Current schedule
All sessions start at noon Eastern time and generally run for 30 minutes. Click on a link below to sign up.


Session Date

Topic

Registration

June 16

Coding for Heart Disease and Heart Arrythmias

Register here

July 19

Coding for Vascular Disease

Register here

Aug. 17

Coding History and Rheumatoid Arthritis

Register here

Sept. 22

Coding Heart Failure, COPD, CHF

Register here

Oct. 11

2023 Updates for ICD-10 CM

Register here

Nov. 16

Coding Scenarios for Specialty Providers and PCPs

Register here

Dec. 8

E/M Coding Review and Scenarios

Register here

If you have any questions about the sessions, contact April Boyce at aboyce@bcbsm.com. If you have questions regarding registration, email Patricia Scarlett at pscarlett@bcbsm.com.


Keep your Provider Authorization form updated

Blue Cross Blue Shield of Michigan is dedicated to safeguarding the protected health information of its members. These safeguards include completion of a Trading Partner Agreement and Provider Authorization form as part of the electronic data interchange setup process. All EDI trading partners must complete the TPA and Provider Authorization form before they can exchange PHI with Blue Cross.

The terms of the TPA require you to notify Blue Cross of any changes in your trading partner information, so it’s important to keep your Provider Authorization form up to date. Updating the form also ensures information is routed to the proper destination.

Update the form when you:

  • Change service bureaus or clearinghouses.
  • Change software vendors.
  • Change billing services.
  • Change submitter IDs.
  • Change 835-file recipients.
  • Change unique 835 receivers or trading partner IDs.
  • Decide you no longer want to receive 835 remittance files.

Review the form when you:

  • Join a new group practice.
  • Leave a group practice and start billing using your own NPI.
  • Hire a new billing service.
  • Start submitting claims through a clearinghouse or when you’ve changed clearinghouses.
  • Select a new destination for your 835.

You don’t need to update the Provider Authorization form if your submitter and trading partner IDs don’t change.

How to change your EDI setup
To make changes to your EDI setup, log in to the Trading Partner Agreement webpage. Or follow the steps below to arrive at the TPA login page at bcbsm.com/providers/help/edi:

  • Visit bcbsm.com/providers.
  • Click on Help.
  • Scroll to the Provider online tools section and click on How do I sign up for Electronic Data Interchange?
  • Click on Trading Partner Agreements.
  • Click on Complete or Update a Provider Authorization.

If you have any questions about EDI enrollment, contact the EDI Help Desk at EDISupport@bcbsm.com. Include your billing NPI and submitter ID with all correspondence.

Pharmacy

Reimbursement for compounded Avastin eye injections changing in August for Medicare Advantage members

For claims received on or after Aug. 1, 2022, reimbursement will change to $160 per eye injected with compounded Avastin® (bevacizumab) eye injections for Medicare Plus Blue℠ and BCN Advantage℠ members.

This change for medical drug claims for Medicare Plus Blue and BCN Advantage members aligns with reimbursement in the marketplace. It’s based on clinical trials that demonstrate the product’s safety and effectiveness.

Here’s the information to include on the claim:

  • HCPCS code number
    • For Medicare Plus Blue: J3590
    • For BCN Advantage: J9035
  • National Drug Code
  • NDC units (example: 0.05 ml)
  • Exact dose in milligrams (example: 1.25 mg)
  • Specific ICD codes pertinent to eye disease

Note: Avastin eye injections don’t require authorization.


Inflectra, Avsola will be preferred infliximab products for pediatric commercial members starting in July

Starting July 1, 2022, the following drugs will be the preferred infliximab products for pediatric Blue Cross Blue Shield of Michigan and Blue Care Network group and individual commercial members:

  • Inflectra® (infliximab-dyyb), HCPCS code Q5103
  • Avsola® (infliximab-axxq), HCPCS code Q5121

The nonpreferred infliximab products will be:

  • Remicade® (infliximab), HCPCS code J1745
  • Renflexis® (infliximab-abda), HCPCS code Q5104

These drugs already require prior authorization for both adult and pediatric members.

How this will affect pediatric members

  • Pediatric members who have an active authorization for a preferred infliximab product as of July 1, 2022, won’t be affected by this change.
  • For pediatric members who have an active authorization for a nonpreferred product, their authorization will remain in effect through Aug. 31, 2022. In addition, we have approved authorizations for Inflectra and Avsola from July 1, 2022, through Aug. 31, 2023, so these members can continue their infliximab therapy without interruption. Health care providers don’t need to submit prior authorization requests for dates of service within this time frame.
  • For pediatric members who will be initiating therapy for an infliximab product, submit a prior authorization request.

How to submit prior authorization requests

Submit prior authorization requests through the NovoLogix® online tool. To learn how, visit ereferrals.bcbsm.com and do the following:

  • For Blue Cross commercial members: Click on Blue Cross and then click on Medical Benefit Drugs. In the Blue Cross commercial column, see the How to submit requests electronically using NovoLogix section.
  • For BCN commercial members: Click on BCN and then click on Medical Benefit Drugs. In the BCN commercial column, see the How to submit requests electronically using NovoLogix section.

Definition of pediatric members

Pediatric members fit into one of these categories:

  • 15 years old or younger, regardless of weight
  • 16 through 18 years old who weigh 50 kilograms or less

Some Blue Cross commercial groups not subject to these requirements

For Blue Cross commercial groups, this authorization requirement applies only to groups that currently participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit. To determine whether a group participates in the prior authorization program, see the Specialty Pharmacy Prior Authorization Master Opt-in/out Group List.

List of requirements

For a full list of requirements related to drugs covered under the medical benefit, see the Blue Cross and BCN utilization management medical drug list for Blue Cross commercial and BCN commercial members.
Authorization isn't a guarantee of payment. As always, health care practitioners should verify eligibility and benefits for our members.


Here are time frames for determinations on authorization requests for acute inpatient medical admissions

The time frame within which Blue Cross Blue Shield of Michigan and Blue Care Network must make a determination on a request to authorize an acute inpatient medical admission depends on the type of request.

We’ve updated the document Submitting acute inpatient authorization requests: Frequently asked question for providers to include information on the time frames for determinations. You can access that document on these webpages:

For easy reference, we also included the details in the table below. This information applies only to acute inpatient medical admissions, not to behavioral health inpatient admissions.

Request for…

Time frame for determination

Requirements

Standard set by …

Blue Cross commercial

Medicare Plus Blue℠

BCN commercial

BCN Advantage℠

Preservice expedited organization determination

Within 72 hours of receipt of request

CMS NCQA

Concurrent expedited organization determination

Within 72 hours of receipt of request

NCQA

Preservice standard organization determination

Within 14 calendar days of receipt of request

CMS NCQA

Concurrent standard organization determination

Within 14 calendar days of receipt of request

 

CMS

Postservice standard organization determination

Within 30 calendar days of receipt of request

CMS NCQA

Here’s more information about the types of requests:

  • Standard: Request to reimburse for services.
  • Expedited: Request when standard time frame could seriously jeopardize the life or health of a member or the member’s ability to regain maximum function. Requires that a physician attest to the need for an expedited request.
  • Preservice: Request is received prior to receipt of care.
  • Concurrent: Request is received while member is receiving care.
  • Postservice: Request is received after member has been discharged.

Reminders:

  • We don’t use the Centers for Medicare & Medicaid Services two-midnight rule; we require authorization for all hospital admissions, both Medicare Advantage and commercial.
  • Our authorization program is oriented toward providers, not members. We don’t deny care, services or treatment. Our program determines the appropriate level of care for reimbursement (observation versus inpatient).

No portion of this publication may be copied without the express written permission of Blue Cross Blue Shield of Michigan, except that BCBSM participating health care providers may make copies for their personal use. In no event may any portion of this publication be copied or reprinted and used for commercial purposes by any party other than BCBSM.

*CPT codes, descriptions and two-digit numeric modifiers only are copyright 2021 American Medical Association. All rights reserved.